BioVie, Inc.
(NASDAQ : BIVI)

( )
BIVI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. -0.77%568.002.7%$659.76m
AMGNAmgen, Inc. 0.00%228.971.3%$587.18m
ILMNIllumina, Inc. 0.05%318.003.5%$555.73m
GILDGilead Sciences, Inc. 0.07%60.251.0%$501.68m
VRTXVertex Pharmaceuticals, Inc. 0.53%212.501.9%$490.94m
ARRYArray BioPharma Inc. -0.36%39.2014.2%$476.66m
MRNAModerna, Inc. 0.56%68.750.0%$474.35m
IMMUImmunomedics, Inc. 0.01%87.8311.0%$373.31m
NVAXNovavax, Inc. -1.22%90.0596.5%$299.11m
ALXNAlexion Pharmaceuticals, Inc. 1.32%119.752.0%$284.12m
BIIBBiogen, Inc. -1.45%265.001.6%$260.75m
EXASEXACT Sciences Corp. 0.00%99.6120.7%$219.55m
BNTXBioNTech SE 1.74%89.250.0%$218.41m
SRNESorrento Therapeutics, Inc. 1.02%7.931.4%$183.18m
SGENSeagen Inc. 0.00%197.716.0%$162.37m

Company Profile

BioVie, Inc. is a development stage biopharmaceutical company, which discovers, develops, and commercializes drug therapies for liver disease. It focuses on BIV201 which treats ascites due to chronic liver cirrhosis. The company was founded on April 10, 2013 and is headquartered in Santa Monica, CA.